Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
European Journal of Nuclear Medicine and Molecular Imaging
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 3/2003

01.03.2003 | Review Article

Radiolabelled peptides for tumour therapy: current status and future directions

Plenary lecture at the EANM 2002

verfasst von: Marion de Jong, Dik Kwekkeboom, Roelf Valkema, Eric P. Krenning

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 3/2003

Einloggen, um Zugang zu erhalten

Abstract

On their plasma membranes, cells express receptor proteins with high affinity for regulatory peptides, such as somatostatin. Changes in the density of these receptors during disease, e.g. overexpression in many tumours, provide the basis for new imaging methods. The first peptide analogues successfully applied for visualisation of receptor-positive tumours were radiolabelled somatostatin analogues. The next step was to label these analogues with therapeutic radionuclides for peptide receptor radionuclide therapy (PRRT). Results from preclinical and clinical multicentre studies have already shown an effective therapeutic response when using radiolabelled somatostatin analogues to treat receptor-positive tumours. Infusion of positively charged amino acids reduces kidney uptake, enlarging the therapeutic window. For PRRT of CCK-B receptor-positive tumours, such as medullary thyroid carcinoma, radiolabelled minigastrin analogues are currently being successfully applied. The combination of different therapy modalities holds interest as a means of improving the clinical therapeutic effects of radiolabelled peptides. The combination of different radionuclides, such as 177Lu- and 90Y-labelled somatostatin analogues, to reach a wider tumour region of high curability, has been described. A variety of other peptide-based radioligands, such as bombesin and NPY(Y1) analogues, receptors for which are expressed on common cancers such as prostate and breast cancer, are currently under development and in different phases of (pre)clinical investigation. Multi-receptor tumour targeting using the combination of bombesin and NPY(Y1) analogues is promising for scintigraphy and PRRT of breast carcinomas and their lymph node metastases.
Literatur
1.
Reubi JC, Krenning E, Lamberts SW, Kvols L. Somatostatin receptors in malignant tissues. J Steroid Biochem Mol Biol 1990; 37:1073–1077.
2.
Reubi JC, Kvols L, Krenning E, Lamberts SW. In vitro and in vivo detection of somatostatin receptors in human malignant tissues. Acta Oncol 1991; 30:463–468.
3.
Reubi JC, Laissue J, Krenning E, Lamberts SW. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol 1992; 43:27–35.
4.
Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20:716–731.
5.
Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L, Lameris JS, Reubi JC, Lamberts SW. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989; 1:242–244.
6.
Krenning EP, Bakker WH, Kooij PP, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-d-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 1992; 33:652–658.
7.
Goldsmith SJ, Kostakoglu L. Role of nuclear medicine in the evaluation of the solitary pulmonary nodule. Semin Ultrasound CT MR 2000; 21:129–138.
8.
Blum J, Handmaker H, Lister-James J, Rinne N. A multicenter trial with a somatostatin analog (99m)Tc depreotide in the evaluation of solitary pulmonary nodules. Chest 2000; 117:1232–1238.
9.
Behr TM, Behe MP. Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med 2002; 32:97–109.
10.
Kwekkeboom DJ, Bakker WH, Kooij PP, Erion J, Srinivasan A, de Jong M, Reubi JC, Krenning EP. Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur J Nucl Med 2000; 27:1312–1317.
11.
van Hagen PM, Breeman WA, Reubi JC, Postema PT, van den Anker-Lugtenburg PJ, Kwekkeboom DJ, Laissue J, Waser B, Lamberts SW, Visser TJ, Krenning EP. Visualization of the thymus by substance P receptor scintigraphy in man. Eur J Nucl Med 1996; 23:1508–1513.
12.
Behr TM, Jenner N, Radetzky S, Behe M, Gratz S, Yucekent S, Raue F, Becker W. Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med 1998; 25:424–430.
13.
Behr TM, Gotthardt M, Barth A, Behe M. Imaging tumors with peptide-based radioligands. Q J Nucl Med 2001; 45:189–200.
14.
Behr TM, Behe M, Angerstein C, Gratz S, Mach R, Hagemann L, Jenner N, Stiehler M, Frank-Raue K, Raue F, Becker W. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential. Clin Cancer Res 1999; 5(10 Suppl):3124s–3138s.
15.
Reubi C, Gugger M, Waser B. Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2002; 29:855–862.
16.
Reubi JC, Gugger M, Waser B, Schaer JC. Y(1)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res 2001; 61:4636–4641.
17.
Reubi JC, Schaer JC, Waser B. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res 1997; 57:1377–1386.
18.
Reubi JC, Laderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res 2000; 60:3105–3112.
19.
Virgolini I, Kurtaran A, Raderer M, et al. Vasoactive intestinal peptide receptor scintigraphy. J Nucl Med 1995; 36:1732–1739.
20.
Virgolini I, Raderer M, Kurtaran A, Angelberger P, Yang Q, Radosavljevic M, Leimer M, Kaserer K, Li SR, Kornek G, Hubsch P, Niederle B, Pidlich J, Scheithauer W, Valent P.123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract. Nucl Med Biol 1996; 23:685–692.
21.
Virgolini I, Szilvasi I, Kurtaran A, Angelberger P, Raderer M, Havlik E, Vorbeck F, Bischof C, Leimer M, Dorner G, Kletter K, Niederle B, Scheithauer W, Smith-Jones P. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients. J Nucl Med 1998; 39:1928–1936.
22.
Weiner RE, Thakur ML. Radiolabeled peptides in the diagnosis and therapy of oncological diseases. Appl Radiat Isot 2002; 57:749–763.
23.
Krenning EP, Kwekkeboom DJ, Oei HY, de Jong RJ, Dop FJ, Reubi JC, Lamberts SW. Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results. Ann N Y Acad Sci 1994; 733:416–424.
24.
Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med 2000; 41:1704–1713.
25.
Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Macke HR. Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000; 27:273–282.
26.
Valkema R, De Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, De Jong FH, Christiansen A, Kam BL, De Herder WW, Stridsberg M, Lindemans J, Ensing G, Krenning EP. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 2002; 32:110–122.
27.
McCarthy KE, Woltering EA, Anthony LB. In situ radiotherapy with111In-pentetreotide. State of the art and perspectives. Q J Nucl Med 2000; 44:88–95.
28.
Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 2002; 32:123–132.
29.
de Jong M, Breeman WA, Bakker WH, Kooij PP, Bernard BF, Hofland LJ, Visser TJ, Srinivasan A, Schmidt MA, Erion JL, Bugaj JE, Macke HR, Krenning EP. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 1998; 58:437–441.
30.
De Jong M, Bakker WH, Breeman WA, Bernard BF, Hofland LJ, Visser TJ, Srinivasan A, Schmidt M, Behe M, Macke HR, Krenning EP. Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Int J Cancer 1998; 75:406–411.
31.
De Jong M, Breeman WAP, Bernard HF, Bakker WH, Van Gameren A, Bugaj JE, Erion J, Srinivasan A, Maecke HR, Krenning EP. Receptor-targeted radionuclide therapy using radiolabelled somatostatin analogues: tumour size versus curability. Eur J Nucl Med 2001; 28:1026P.
32.
de Jong M, Breeman WA, Bernard BF, Bakker WH, Visser TJ, Kooij PP, van Gameren A, Krenning EP. Tumor Response After [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med 2001; 42:1841–1846.
33.
Virgolini I, Patri P, Novotny C, Traub T, Leimer M, Fuger B, Li SR, Angelberger P, Raderer M, Wogritsch S, Kurtaran A, Kletter K, Dudczak R. Comparative somatostatin receptor scintigraphy using In-111-DOTA-lanreotide and In-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. Ann Oncol 2001; 12 (Suppl 2):S41–S45.
34.
Heppeler A, Froidevaux S, Mäcke HR, Jermann E, Béhé M, Powell P, Hennig M. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. Chem Eur J 1999; 5:1974–1981.
35.
Kwekkeboom DJ, Kooij PP, Bakker WH, Macke HR, Krenning EP. Comparison of111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J Nucl Med 1999; 40:762–767.
36.
Chinol M, Bodei L, Cremonesi M, Paganelli G. Receptor-mediated radiotherapy with Y-DOTA-dPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group. Semin Nucl Med 2002; 32:141–147.
37.
Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, Bartolomei M, Orsi F, De Cicco C, Macke HR, Chinol M, de Braud F. Receptor-mediated radiotherapy with90Y-DOTA-d-Phe1-Tyr3-octreotide. Eur J Nucl Med 2001; 28:426–434.
38.
Paganelli G, Bodei L, Chinol M, Zoboli S, Cremonesi M, Gatti M, Bartolomei M, Grana C, Maecke H. Receptor mediated radiotherapy with90Y-DOTATOC: results of a phase I study. J Nucl Med 2001; 42:36P.
39.
Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [90Y-DOTA]-d-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001; 12:941–945.
40.
Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, Haldemann A, Mueller-Brand J. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq90Y-DOTATOC. J Nucl Med 2002; 43:610–616.
41.
Waldherr C, Schumacher T, Maecke HR, Schirp U, Forrer F, Nitzsche EU, Mueller-Brand J. Does tumor response depend on the number of treatment sessions at constant injected dose using 90yttrium-DOTATOC in neuroendocrine tumors? Eur J Nucl Med 2002; 29:S100.
42.
De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S, Krenning EP. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002; 32:133–140.
43.
Smith MC, Liu J, Chen T, Schran H, Yeh CM, Jamar F, Valkema R, Bakker W, Kvols L, Krenning E, Pauwels S. OctreoTher: ongoing early clinical development of a somatostatin- receptor-targeted radionuclide antineoplastic therapy. Digestion 2000; 62 (Suppl 1):69–72.
44.
Valkema R, Kvols L, Jamar F, Bakker WH, Smith C, Krenning EP, Pauwels S. Phase 1 study of therapy with90Y-SMT487 (OctreoTher) in patients with somatostatin receptor-positive tumors. J Nucl Med 2002; 43:33P.
45.
Jonard P, Jamar F, Walrand S, Collart JP, Valkema R, Bakker WH, Labar D, Smith C, Kvols L, Krenning EP, Pauwels S. Tumor dosimetry based on PET86Y-DOTA-Tyr3-octreotide (SMT487) and CT-scan predicts tumor response to 90Y-SMT487 (OctreoTher). J Nucl Med 2000; 41:111P.
46.
Schumacher T, Hofer S, Eichhorn K, Wasner M, Zimmerer S, Freitag P, Probst A, Gratzl O, Reubi JC, Maecke R, Mueller-Brand J, Merlo A. Local injection of the90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study. Eur J Nucl Med Mol Imaging 2002; 29:486–493.
47.
Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002; 32:148–155.
48.
Virgolini I, Kurtaran A, Angelberger P, Raderer M, Havlik E, Smith-Jones P. "MAURITIUS": tumour dose in patients with advanced carcinoma. Ital J Gastroenterol Hepatol 1999; 31 (Suppl 2):S227–S230.
49.
Virgolini I, Traub T, Novotny C, Leimer M, Fuger B, Li SR, Patri P, Pangerl T, Angelberger P, Raderer M, Burggasser G, Andreae F, Kurtaran A, Dudczak R. Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curr Pharm Des 2002; 8:1781–1807.
50.
Kwekkeboom DJ, Bakker WH, Kooij PPM, Konijnenberg MW, Srinivasan A, Erion JL, Schmidt MA, Bugaj JE, de Jong M, Krenning EP. [177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med 2001; 28:1319–1325.
51.
de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, Bugaj JE, Erion J, Schmidt M, Srinivasan A, Krenning EP. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001; 92:628–633.
52.
Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate. Eur J Nucl Med (in press). DOI 10.1007/s00259-002-1050-8.
53.
Cybulla M, Weiner SM, Otte A. End-stage renal disease after treatment with90Y-DOTATOC. Eur J Nucl Med 2001; 28:1552–1554.
54.
Behr TM, Behe M, Kluge G, Gotthardt M, Schipper ML, Gratz S, Arnold R, Becker W, Goldenberg DM. Nephrotoxicity versus anti-tumour efficacy in radiopeptide therapy: facts and myths about the Scylla and Charybdis. Eur J Nucl Med Mol Imaging 2002; 29:277–279.
55.
Boerman OC, Oyen WJ, Corstens FH. Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney. Eur J Nucl Med 2001; 28:1447–1449.
56.
Valkema R, de Jong M, Kooij PPM, Kwekkeboom D, Krenning EP. Effective and safe inhibition of renal uptake of radiolabeled peptides by combined lysine and arginine infusion. J Nucl Med 2001; 42:37P.
57.
Rolleman EJ, Valkema R, de Jong M, Kooij PPM, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 2003; 30:9–15.
58.
Reubi JC, Waser B, Laderach U, Stettler C, Friess H, Halter F, Schmassmann A. Localization of cholecystokinin A and cholecystokinin B-gastrin receptors in the human stomach. Gastroenterology 1997; 112:1197–1205.
59.
de Jong M, Bakker WH, Bernard BF, Valkema R, Kwekkeboom DJ, Reubi JC, Srinivasan A, Schmidt M, Krenning EP. Preclinical and initial clinical evaluation of111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med 1999; 40:2081–2087.
60.
Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer JC, Gugger M. Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[d-Tyr(6), beta-Ala(11), Phe(13), NLE(14)] bombesin(6-14). Clin Cancer Res 2002; 8:1139–1146.
61.
Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 1999; 59:1152–1159.
62.
Schmitt JS, Wild D, Ginj M, Reubi JC, Waser B, De Jong M, Bernard HF, Krenning EP, Maecke HR. DOTA-NOC, a high affinity ligand of the somatostatin receptor subtypes 2,3 and 5 for radiotherapy. J Labelled Cpd Radiopharm 2001; 44:s697–s699.
63.
O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides [see comments]. J Nucl Med 1995; 36:1902–1909.
64.
De Jong M, Bernard HF, Breeman WAP, van Gameren A, Krenning EP. Combination of90Y- and 177Lu-labeled somatostatin analogs is superior for radionuclide therapy compared to 90Y- or 177Lu-labeled analogs only. J Nucl Med 2002; 43:123P–124P.
65.
Gugger M, Reubi JC. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol 1999; 155:2067–2076.
66.
De Vincentis G, Scopinaro F, Varvarigou A, Ussof W, Schillaci O, Archimandritis , Corleto V, Longo F, Delle Fave G. Phase I trial of technetium [Leu13] bombesin as cancer seeking agent: possible scintigraphic guide for surgery? Tumori 2002; 88:S28–S30.
67.
Scopinaro F, Varvarigou A, Ussof W, De Vincentis G, Archimandritis S, Evangelatos G, Corleto V, Pulcini A, Capoccetti F, Remediani S, Massa R. Breast cancer takes up99mTc bombesin. A preliminary report. Tumori 2002; 88:S25–S28.
Metadaten
Titel
Radiolabelled peptides for tumour therapy: current status and future directions
Plenary lecture at the EANM 2002
verfasst von
Marion de Jong
Dik Kwekkeboom
Roelf Valkema
Eric P. Krenning
Publikationsdatum
01.03.2003
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 3/2003
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-002-1107-8

Weitere Artikel der Ausgabe 3/2003

European Journal of Nuclear Medicine and Molecular Imaging 3/2003 Zur Ausgabe

Original Article

Bilateral increase in striatal dopamine D2 receptor density in the 6-hydroxydopamine-lesioned rat: a serial in vivo investigation with small animal PET

Letter to the Editor

Do we read carefully?

Controversies—Against

Do we need more nuclear cardiologists in Europe?

Original Article

Quantitative estimation of myocardial salvage after primary percutaneous transluminal coronary angioplasty in patients with angiographic no reflow

Book reviews

Oncologic Imaging

Letter to the Editor

PET-CT: a matter of opinion?